SCHEMBL689542

SCHEMBL689542

NC(=O)NCc1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.66
CYP2C9 P11712 1/20 0.66
LMNA P02545 2/20 0.61
PLA2G1B P04054 2/20 0.59
ATG4B Q9Y4P1 2/20 0.59
HTT P42858 1/20 0.58
HPGD P15428 3/20 0.56
RAB9A P51151 3/20 0.56
ALDH1A1 P00352 1/20 0.56
KMT2A Q03164 2/20 0.54
POLB P06746 2/20 0.54
TP53 P04637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NPC1 O15118 1/20 0.54
MAOB P27338 1/20 0.54
CYP1A2 P05177 1/20 0.53
TSHR P16473 1/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18415459 0.83 LMNA (0.66) CYP2C19LMNAPLA2G1BATG4BHTT
SCHEMBL6468546 0.83 RAB9A (0.68) LMNAPLA2G1BATG4BHTTHPGD
SCHEMBL29484159 0.82 PLA2G1B (0.68) LMNAPLA2G1BATG4BHPGDALDH1A1
SCHEMBL8245710 0.81 CYP2C9 (0.68) CYP2C19CYP2C9KMT2APOLBCYP1A2
SCHEMBL27589884 0.81 CYP2C9 (0.68) CYP2C19CYP2C9KMT2ACA12CA1
SCHEMBL8139643 0.81 CYP2C9 (0.68) CYP2C19CYP2C9LMNAHPGDKMT2A
SCHEMBL2553685 0.81 HTT (0.65) CYP2C19CYP2C9LMNAPLA2G1BATG4B
SCHEMBL626651 0.81 TPSAB1 (0.70) CYP2C19CYP2C9KMT2ACYP1A2TSHR
SCHEMBL21776624 0.80 LMNA (0.49) CYP2C19CYP2C9LMNAPLA2G1BATG4B
SCHEMBL14893159 0.80 HPGD (0.60) LMNAHPGDRAB9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114786774-A Novel compounds 维科尔药物公司 2022-07-22 CN claimed
EP-1124811-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 2001-08-22 EP claimed
WO-2000026203-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2000-05-11 WO claimed
CN-118373777-A Pyrimidine diketone derivative and preparation method and application thereof 河北科技大学 2024-07-23 CN disclosed
CN-115322176-B 2, 3-dihydrobenzofuranyl substituted 1H-indazole compound and preparation and application thereof 温州医科大学 2024-04-16 CN disclosed
CN-117466803-A Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2024-01-30 CN disclosed
CN-111132976-B Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2023-08-22 CN disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
CN-115322176-A 2, 3-dihydrobenzofuranyl substituted 1H-indazole compound and preparation and application thereof 温州医科大学 2022-11-11 CN disclosed
CN-114786774-A Novel compounds 维科尔药物公司 2022-07-22 CN disclosed
WO-2021242923-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2021-12-02 WO disclosed
US-6486178-B1 Indane derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2002-11-26 US disclosed
EP-1085009-A1 INDAN DERIVATIVES Nissan Chemical Industries, Ltd. (JP) 2001-03-21 EP disclosed
US-6066631-A Chroman derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-05-23 US disclosed
WO-2000012492-A1 BENZOXAZINE DERIVATIVES NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-03-09 WO disclosed
EP-0934296-A1 CHROMAN DERIVATIVES NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1999-08-11 EP disclosed
EP-0874823-A1 TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1998-11-04 EP disclosed
US-5798373-A Tri-substituted phenyl derivatives useful as PDE IV inhibitors CELLTECH THERAPEUTICS, LIMITED (GB) 1998-08-25 US disclosed
WO-1998004542-A1 CHROMAN DERIVATIVES NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-05 WO disclosed
WO-1997023460-A1 TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 CYP2C19 1593/4885CYP2C9 1927/4885LMNA 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.